Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2003Current Medicinal ChemistryOpen Access

Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus

View Full Paper
Ask AI
Bookmark
Share

Authors

GHGeorge G. HolzSUNY Upstate Medical UniversityOCOleg G. ChepurnySUNY Upstate Medical University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Holz et al. (2003) studied this question.

synapsesocial.com/papers/6a70e532b5c1fe5ca9dfc54chttps://doi.org/10.2174/0929867033456648
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients1996 · 336 citations
  2. 2Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.1999 · 338 citations
  3. 3Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.1998 · 113 citations
  4. 4Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans1994 · 904 citations
  5. 5Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in Type 2 diabetic patients1998 · 53 citations